跳转至内容
Merck

V-016

Supelco

烟酰胺 (维生素B3)标准液 CRM 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

别名:

烟酰胺, 维生素 B3, 吡啶-3-甲酰胺, 烟碱酰胺, 维生素 PP

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C6H6N2O
CAS号:
分子量:
122.12
Beilstein:
383619
EC號碼:
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

certified reference material

形狀

liquid

特點

Snap-N-Spike®/Snap-N-Shoot®

包裝

ampule of 1 mL

製造商/商標名

Cerilliant®

濃度

1.0 mg/mL in methanol

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

mp

128-131 °C (lit.)

應用

clinical testing
clinical testing

格式

single component solution

儲存溫度

−20°C

SMILES 字串

NC(=O)c1cccnc1

InChI

1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)

InChI 密鑰

DFPAKSUCGFBDDF-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

烟酰胺也称为烟碱酰胺或尼古丁酰胺。它是植物和动物食物中维生素B3的水溶性形式,并主要用作膳食补充剂。

應用

认证加标溶液适用于多种测试应用,包括通过 HPLC 对药物制剂或膳食补充剂进行的质量控制测试。
烟酰胺可作为分析参考标准品,用于通过经电喷雾质谱确证的平面色谱多重检测对功能饮料中的分析物、通过紫外-可见分光光度法和多元分析对药物制剂中的分析物进行测定。

生化/生理作用

烟酰胺是维生素B3的酰胺衍生物,是PARP抑制剂

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

相關產品

产品编号
说明
价格

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

標靶器官

Eyes

儲存類別代碼

3 - Flammable liquids

水污染物質分類(WGK)

WGK 2

閃點(°F)

49.5 °F - closed cup

閃點(°C)

9.7 °C - closed cup


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Simultaneous determination of riboflavin, pyridoxine, nicotinamide, caffeine and taurine in energy drinks by planar chromatography-multiple detection with confirmation by electrospray ionization mass spectrometry
Aranda M and Morlock G
Journal of Chromatography A, 1131(1-2), 253-260 (2006)
Simultaneous determination and classification of riboflavin, thiamine, nicotinamide and pyridoxine in pharmaceutical formulations, by UV-visible spectrophotometry and multivariate analysis
Lopez-de-Alba LP, et al.
Journal of the Brazilian Chemical Society, 17(4), 715-722 (2006)
Takeshi Natori et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 40(5), 635-637 (2013-07-19)
Sorafenib is an oral multi-kinase inhibitor that targets tumor growth and angiogenesis signal transduction pathways. Two global phase III trials showed that sorafenib prolonged the survival of patients with advanced hepatocellular carcinoma (HCC). Based on the positive results of these
Case of sorafenib-induced thyroid storm.
Sigurdis Haraldsdottir et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(16), e262-e264 (2013-04-24)
Noriaki Kitada et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 40(4), 479-482 (2013-07-16)
The current status of treatment with sorafenib, and factors affecting the duration of treatment in patients started on sorafenib for hepatocellular carcinoma from July 2009 until April 2011 in the Department of Gastroenterology at Kobe City Medical Center General Hospital

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门